Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast

The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—Janssen’s Tremfya and AbbVie’s Rinvoq and Skyrizi. Furthermore, a series of approvals expected in the next decade will likely present a challenge to the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies and drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to capture substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the positions of current market leaders. The impending entry of the first TYK2 inhibitor (BMS’s deucravacitinib), an additional IL-17 inhibitor (UCB’s bimekizumab), and an IL-23 inhibitor (Sun Pharma’s tildrakizumab) will also create interesting market dynamics.

Questions answered

  • What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in different markets react to these less-expensive therapies?
  • How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What is the physician perception of these therapies?
  • Which emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? What novel mechanisms of action are considered good clinical targets for this disease?
  • Which unmet needs remain in the treatment of PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?

Content highlights:

Geographies: United States, EU5, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.

Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2031, segmented by brands / generics.

Emerging therapies: Phase III/PR: 3 drugs; Phase II: 5 drugs.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution enhancement

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • Key updates
        • August 2023
        • May 2023
        • March 2023
        • Q4 2022
          • December 2022
          • October 2022
        • Q3 2022
          • September 2022
          • August 2022
          • July 2022
        • Q2 2022
          • June 2022
          • May 2022
          • April 2022
      • Market outlook
        • Key findings
          • Market share of drug classes for PsA: 2021
          • Market share of drug classes for PsA: 2031
          • PsA SWOT analysis
        • Market drivers and constraints
          • What factors are driving the market for PsA?
          • What factors are constraining the market for PsA?
          • Annual sales of TNF inhibitors in PsA: 2021-2031
          • Annual sales of select drugs in PsA: 2021-2031
        • Drug-class-specific trends
          • U.S. patient share for TNF inhibitors in PsA: 2021-2031
          • EU5 patient share for TNF inhibitors in PsA: 2021-2031
          • Japanese patient share for TNF inhibitors in PsA: 2021-2031
          • Major-market brand and biosimilar sales of ustekinumab in PsA: 2021-2031
          • Patient share of ustekinumab for PsA in the United States, EU5, and Japan: 2021-2031
          • Major-market sales of IL-17 inhibitors for PsA: 2021-2031
          • Major-market patient share of IL-17 inhibitors in PsA: 2021-2031
          • Major-market sales and patient share of IL-23 inhibitors in PsA: 2021-2031
          • Sales of apremilast for PsA in the United States, EU5, and Japan: 2021-2031
          • Major-market patient share and sales of JAK inhibitors in PsA: 2021-2031
          • Major-market patient share of PDE4, JAK, and TYK2 inhibitors in PsA: 2021-2031
          • Sales of abatacept for PsA in the United States and EU5: 2021-2031
      • Forecast
        • Market forecast assumptions
        • Market forecast dashboard
      • Etiology and pathophysiology
        • Disease overview
          • Etiology
            • Risk factors for PsA
          • Pathophysiology
            • Clinical, extra-articular, and radiographic features of various spondyloarthropathies
            • Pathogenesis
            • Pathological changes in early and late PsA
          • Key pathways and drug targets
            • Pathogenesis and drug targets
        • Epidemiology
          • Key findings
            • Epidemiology populations
              • Disease definition, methods, and sources used
              • Total prevalent cases of psoriatic arthritis: 2022-2032 (thousands)
              • Sources used for diagnosed prevalence of psoriatic arthritis
              • Diagnosed prevalent cases of psoriatic arthritis: 2021-2031 (thousands)
              • Sources used for diagnosed drug-treated prevalence of psoriatic arthritis
              • Diagnosed drug-treated prevalent cases of psoriatic arthritis: 2021-2031 (thousands)
          • Current treatment
            • Key findings
              • Treatment goals
                • Key endpoints used in clinical trials for PsA
              • Key current therapies
                • Overview
                • Mechanism of action of key current drug classes used for PsA
                • Current treatments used for PsA
                • Market events impacting the use of key current therapies in PsA
                • Advantages and disadvantages of TNF-u03b1 inhibitors
                • Expert insight: TNF inhibitors
                • Advantages and disadvantages of ustekinumab
                • Ongoing clinical development
                • Expert insight: ustekinumab
                • Advantages and disadvantages of secukinumab
                • Ongoing clinical development
                • Expert insight: secukinumab
                • Advantages and disadvantages of brodalumab
                • Advantages and disadvantages of ixekizumab
                • Advantages and disadvantages of guselkumab
                • Ongoing clinical development
                • Expert insight: guselkumab
                • Risankizumab
                • Advantages and disadvantages of risankizumab
                • Expert insight: risankizumab
                • Advantages and disadvantages of tofacitinib
                • Expert insight: tofacitinib
                • Upadacitinib
                • Advantages and disadvantages of upadacitinib
                • Expert insight: upadacitinib
                • Advantages and disadvantages of apremilast
                • Ongoing clinical development
                • Expert insight: apremilast
                • Advantages and disadvantages of abatacept
                • Expert insight: abatacept
                • Advantages and disadvantages of cDMARDs
                • Expert insight: cDMARDs
              • Medical practice
                • Overview
                • Factors influencing drug selection in PsA
                • Treatment decision tree for PsA: United States
                • Treatment decision tree for PsA: Europe
                • Treatment decision tree for PsA: Japan
            • Unmet need overview
              • Current and future attainment of unmet needs in PsA
              • Top unmet needs in PsA: current and future attainment
              • Expert insight: unmet need in PsA
            • Drug pipeline
              • Pipeline
              • Regulatory Milestones
              • Indication Comparison
            • Emerging therapies
              • Key findings
                • Key emerging therapies
                  • Key emerging therapies in development for PsA
                  • Estimated launch dates of key emerging therapies for the treatment of PsA
                  • Bimekizumab profile
                  • Key ongoing clinical trials of bimekizumab in the treatment of PsA
                  • Analysis of the clinical development program for bimekizumab
                  • Expert insight: bimekizumab
                  • Expectations for launch and sales opportunity of bimekizumab in psoriatic arthritis
                  • Tildrakizumab profile
                  • Key ongoing clinical trials of tildrakizumab in the treatment of PsA
                  • Analysis of the clinical development program for tildrakizumab
                  • Expert insight: tildrakizumab
                  • Expectations for launch and sales opportunity of tildrakizumab in PsA
                  • Deucravacitinib profile
                  • Key ongoing clinical trials of deucravacitinib in the treatment of psoriatic arthritis
                  • Analysis of the clinical development program for deucravacitinib
                  • Expert insight: deucravacitinib
                  • Expectations for launch and sales opportunity of deucravacitinib in psoriatic arthritis
                • Early-phase pipeline analysis
                  • Select compounds in early-phase development for PsA
              • Access and reimbursement overview
                • Region-specific reimbursement practices
                  • General reimbursement environment: United States
                  • General reimbursement environment: EU5
                  • General reimbursement environment: Japan
              • Appendix
                • Abbreviations
                • Bibliography

            Login to access report

            launch Related Market Assessment Reports